Bank of America upgraded shares of Stoke Therapeutics (NASDAQ:STOK – Get Rating) from an underperform rating to a neutral rating in a research note released on Monday, The Fly reports. The firm currently has $12.00 price objective on the stock, up from their previous price objective of $9.00. Several other analysts have also weighed in […]
UBS Group AG lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) by 299.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,738 shares of the company’s stock after purchasing an additional 11,046 shares […]
Research analysts at Canaccord Genuity Group started coverage on shares of Stoke Therapeutics (NASDAQ:STOK – Get Rating) in a research note issued to investors on Wednesday, FinViz reports. The brokerage set a “buy” rating and a $24.00 price target on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 169.06% from the […]
Should You Buy or Sell Stoke Therapeutics Stock? Get The Latest STOK Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.